{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:57:00Z","timestamp":1790679420953,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2026,7,6]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hereditary cancer syndromes (HCSs) account for approximately 5\u201310% of all cancers and are frequently associated with pathogenic variants (PVs) in genes such as\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      . Nevertheless, a substantial proportion of individuals with strong familial cancer aggregation remain genetically unexplained after standard multigene panel testing. Clinical exome sequencing (CES) may overcome this limitation by enabling a broader exploration of cancer susceptibility genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 500 high-risk patients who previously tested negative for\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      PVs. All samples were analysed using next-generation sequencing technology. Initially, a 60-gene filtered panel recommended by the American Society of Clinical Oncology (ASCO) guidelines was applied, followed by a 102-gene filtered panel derived from CES to identify additional PVs or likely PVs (LPVs) beyond current diagnostic panels. Variant classification was performed according to the American College of Medical Genetics and Genomics\/Association for Molecular Pathology guidelines, incorporating ClinGen and gene-specific expert curation recommendations when available.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Within the ASCO panel, PV\/LPVs were identified in 9% of patients while 35% carried variants of uncertain significance. CES identified additional PVs\/LPVs in 5% of patients in genes not currently included in ASCO-recommended surveillance panels, such as\n                      <jats:italic>RAD50<\/jats:italic>\n                      ,\n                      <jats:italic>BLM<\/jats:italic>\n                      ,\n                      <jats:italic>WRN<\/jats:italic>\n                      ,\n                      <jats:italic>PMS1<\/jats:italic>\n                      and\n                      <jats:italic>FANCA<\/jats:italic>\n                      . These variants may represent candidate susceptibility loci requiring further clinical and functional validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      CES may provide additional exploratory genomic information in selected high-risk\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      -negative patients, particularly when standard panel testing is uninformative. Although many of the additional findings identified are not yet clinically actionable, CES represents a valuable resource for future reinterpretation as gene\u2013disease evidence evolves. Overall, our findings support the use of CES as a second-tier exploratory approach in carefully selected high-risk cases, while emphasising the need for cautious interpretation and continued gene\u2013disease curation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmg-2026-111497","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:20:19Z","timestamp":1784913619000},"page":"656-664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Potential advantage of clinical exome sequencing in\n                    <i>BRCA1\/2<\/i>\n                    -negative families: a retrospective study of a cohort of 500 patients at a high-risk for hereditary cancers"],"prefix":"10.1136","volume":"63","author":[{"given":"Anastasia","family":"Dell\u2019Elice","sequence":"first","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Human Sciences, Law, and Economics, Telematic University \u2018Leonardo Da Vinci\u2019-UNIDAV, Torrevecchia Teatina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Palmarini","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Neurosciences, Imaging and Clinical Sciences, \u2018G. d\u2019Annunzio\u2019 University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9056-2825","authenticated-orcid":false,"given":"Federico","family":"Anaclerio","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Imaging and Clinical Sciences, \u2018G. d\u2019Annunzio\u2019 University of Chieti-Pescara, Chieti, Italy"},{"name":"Center for Advanced Studies and Technology (CAST), Gabriele d\u2019Annunzio University of Chieti and Pescara Department of Sciences, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Pilenzi","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Neurosciences, Imaging and Clinical Sciences, \u2018G. d\u2019Annunzio\u2019 University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Department of Hematology, Pescara Hospital, Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Palka","sequence":"additional","affiliation":[{"name":"UOC Genetica Medica, SS Annunziata Hospital, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tinari","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Medical, Oral and Biotechnological Sciences, d\u2019Annunzio University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Grassadonia","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Medical, Oral and Biotechnological Sciences, d\u2019Annunzio University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ballerini","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Innovative Technologies in Medicine and Dentistry, \u2018G. d\u2019Annunzio\u2019 University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Grossi","sequence":"additional","affiliation":[{"name":"Breast Unit, PO \u2018G. Bernabeo\u2019, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vitali","sequence":"additional","affiliation":[{"name":"Breast Unit, PO \u2018G. Bernabeo\u2019, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Secondi","sequence":"additional","affiliation":[{"name":"Plastic and Reconstructive Surgery, Tor Vergata University, Chieti, Italy"},{"name":"Clinical Oncology Unit, SS Annunziata Hospital, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Amerio","sequence":"additional","affiliation":[{"name":"Dermatology Department of Medicine and Aging Science, University of Chieti Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gatta","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Neurosciences, Imaging and Clinical Sciences, \u2018G. d\u2019Annunzio\u2019 University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liborio","family":"Stuppia","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Neurosciences, Imaging and Clinical Sciences, \u2018G. d\u2019Annunzio\u2019 University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Antonucci","sequence":"additional","affiliation":[{"name":"Center for Advanced Studies and Technology (CAST), d\u2019Annunzio\u201d University of Chieti-Pescara, Chieti, Italy"},{"name":"Department of Neurosciences, Imaging and Clinical Sciences, \u2018G. d\u2019Annunzio\u2019 University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026092903151196000_63.10.656.1","doi-asserted-by":"crossref","DOI":"10.3390\/genes14051025","article-title":"Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool","volume":"14","author":"Garutti","year":"2023","journal-title":"Genes (Basel)"},{"key":"2026092903151196000_63.10.656.2","unstructured":"American Cancer Society . Available: https:\/\/www.cancer.org\/cancer\/risk-prevention\/genetics\/genetic-testing-for-cancer-risk\/understanding genetic-testing-for-cancer.html"},{"key":"2026092903151196000_63.10.656.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132327","article-title":"The Crucial Role of Hereditary Cancer Panel Testing in Unaffected Individuals with a Strong Family History of Cancer: A Retrospective Study of a Cohort of 103 Healthy Subjects","volume":"16","author":"Pilenzi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026092903151196000_63.10.656.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98737-8","article-title":"Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design","volume":"11","author":"Blomen","year":"2021","journal-title":"Sci Rep"},{"key":"2026092903151196000_63.10.656.5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.seminoncol.2020.05.008","article-title":"Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers","volume":"47","author":"Pederson","year":"2020","journal-title":"Semin Oncol"},{"key":"2026092903151196000_63.10.656.6","doi-asserted-by":"publisher","DOI":"10.1101\/gad.334516.119"},{"key":"2026092903151196000_63.10.656.7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13193-011-0049-7","article-title":"BRCA1 and BRCA1 Genes and Inherited Breast and\/or Ovarian Cancer: Benefits of Genetic Testing","volume":"1","author":"Somasundaram","year":"2010","journal-title":"Indian J Surg Oncol"},{"key":"2026092903151196000_63.10.656.8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/jhg.2016.138","article-title":"Comparison between CaGene 5.1 and 6.0 for BRCA1\/2 mutation prediction: a retrospective study of 150 BRCA1\/2 genetic tests in 517 families with breast\/ovarian cancer","volume":"62","author":"Antonucci","year":"2017","journal-title":"J Hum Genet"},{"key":"2026092903151196000_63.10.656.9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-319-70197-4_8","article-title":"Multi-gene Panel Testing in Breast Cancer Management","volume":"173","author":"Fountzilas","year":"2018","journal-title":"Cancer Treat Res"},{"key":"2026092903151196000_63.10.656.10","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1060504","article-title":"Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis","volume":"14","author":"Anaclerio","year":"2023","journal-title":"Front Genet"},{"key":"2026092903151196000_63.10.656.11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ccr3.718","article-title":"A new case of \u201cde novo\u201d BRCA1 mutation in a patient with early-onset breast cancer","volume":"5","author":"Antonucci","year":"2017","journal-title":"Clin Case Rep"},{"key":"2026092903151196000_63.10.656.12","unstructured":"NCCN . Detection, prevention, and risk reduction. Available: https:\/\/www.nccn.org\/guidelines\/category_2 [Accessed 10 Oct 2023]."},{"key":"2026092903151196000_63.10.656.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2599"},{"key":"2026092903151196000_63.10.656.14","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-023-00455-x","article-title":"Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases","volume":"17","author":"Alix","year":"2023","journal-title":"Hum Genomics"},{"key":"2026092903151196000_63.10.656.15","doi-asserted-by":"crossref","DOI":"10.3390\/genes14030646","article-title":"SDHA Germline Mutations in SDH-Deficient GISTs: A Current Update","volume":"14","author":"Schipani","year":"2023","journal-title":"Genes (Basel)"},{"key":"2026092903151196000_63.10.656.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70007-3"},{"key":"2026092903151196000_63.10.656.17","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109341"},{"key":"2026092903151196000_63.10.656.18","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.566266","article-title":"New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients","volume":"11","author":"Djursby","year":"2020","journal-title":"Front Genet"},{"key":"2026092903151196000_63.10.656.19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4266"},{"key":"2026092903151196000_63.10.656.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-023-01484-0","article-title":"Genetic contribution of caspase-8 variants and haplotypes to breast cancer risk and prognosis: a case-control study in Iran","volume":"16","author":"Afzaljavan","year":"2023","journal-title":"BMC Med Genomics"},{"key":"2026092903151196000_63.10.656.21","doi-asserted-by":"crossref","first-page":"14436","DOI":"10.3390\/ijms232214436","article-title":"TGF-\u03b2 Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026092903151196000_63.10.656.22","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1093\/hmg\/ddl486","article-title":"TGF-beta signaling alterations and susceptibility to colorectal cancer","volume":"16 Spec No 1","author":"Xu","year":"2007","journal-title":"Hum Mol Genet"},{"key":"2026092903151196000_63.10.656.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-687830"},{"key":"2026092903151196000_63.10.656.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168260"},{"key":"2026092903151196000_63.10.656.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508054"},{"key":"2026092903151196000_63.10.656.26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000901"},{"key":"2026092903151196000_63.10.656.27","doi-asserted-by":"publisher","DOI":"10.1038\/32688"},{"key":"2026092903151196000_63.10.656.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006565"},{"key":"2026092903151196000_63.10.656.29","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-022-00435-7","article-title":"Whole-exome sequencing of BRCA-negative breast cancer patients and case-control analyses identify variants associated with breast cancer susceptibility","volume":"16","author":"Lee","year":"2022","journal-title":"Hum Genomics"},{"key":"2026092903151196000_63.10.656.30","doi-asserted-by":"crossref","DOI":"10.3390\/genes13081296","article-title":"The Identification by Exome Sequencing of Candidate Genes in BRCA-Negative Tunisian Patients at a High Risk of Hereditary Breast\/Ovarian Cancer","volume":"13","author":"BenAyed-Guerfali","year":"2022","journal-title":"Genes (Basel)"},{"key":"2026092903151196000_63.10.656.31","doi-asserted-by":"crossref","DOI":"10.1007\/s10689-025-00471-x","article-title":"Detection rates of multigene panel and exome testing in patients with previous negative BRCA1\/2 results","volume":"24","author":"Wasson","year":"2025","journal-title":"Fam Cancer"},{"key":"2026092903151196000_63.10.656.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01239"},{"key":"2026092903151196000_63.10.656.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.06.003"},{"key":"2026092903151196000_63.10.656.34","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-104588"},{"key":"2026092903151196000_63.10.656.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.743"},{"key":"2026092903151196000_63.10.656.36","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgq047"},{"key":"2026092903151196000_63.10.656.37","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"2026092903151196000_63.10.656.38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cancergen.2018.04.002","article-title":"Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent","volume":"224\u2013225","author":"Powis","year":"2018","journal-title":"Cancer Genet"},{"key":"2026092903151196000_63.10.656.39","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a034579","article-title":"Whole-Genome Sequencing in Cancer","volume":"9","author":"Zhao","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026092903151196000_63.10.656.40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1418631112"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2026-111497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:15:43Z","timestamp":1790676943000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2026-111497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jmg-2026-111497"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2026-111497","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}